企業プロフィール
Kezar Life Sciences 株価・ニュース・カタリスト
- ティッカー:
- KZR
- 取引所:
- NASDAQ
- セクター:
- Life Science Tools
- 所在地:
- United States
株価パフォーマンス
7.29 USD (-0.95%)
終値
最終更新: 2026年5月8日
53.9M USD
時価総額
株価変動の要因
KZR の終値変動に関する情報は現在取得できません。
企業概要
Immunology-Focused Biotechnology Company
Kezar Life Sciences has focused on small-molecule therapies for immune-mediated diseases. Following portfolio reductions and operational restructuring, its principal remaining development asset is zetomipzomib.
Zetomipzomib Mechanism
Zetomipzomib is a selective inhibitor of the immunoproteasome, a protein-degradation complex enriched in immune cells. By modulating immunoproteasome activity, the candidate is intended to reduce inflammatory signaling and pathogenic immune-cell activity without broadly suppressing the constitutive proteasome.
Autoimmune Hepatitis Program
The lead indication is relapsed or refractory autoimmune hepatitis, a chronic inflammatory liver disease commonly managed with long-term corticosteroids and other immunosuppressive drugs. Kezar has sought a development strategy that could demonstrate disease control while reducing steroid exposure.
PORTOLA Clinical Evidence
The randomized Phase 2a PORTOLA study evaluated zetomipzomib in patients inadequately controlled by standard therapy. Results supported clinically meaningful steroid-sparing remissions and provided the clinical basis for discussions about a potential global Phase 2b program.
Focused Strategic Position
Kezar discontinued its KZR-261 trial and sold its Sec61 discovery assets, concentrating remaining value on zetomipzomib and associated partnership rights. The company has also been evaluating strategic alternatives for the asset and the broader business.
今後のカタリスト
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。